Potential candidates for CAR-T therapy for neuroblastoma and other solid tumors include several targets, such as L1-CAM, tumor-associated glypicans (GPC2, GPC3), and B7-H3 [4]. This evidence concerns the gene CD276 and neuroblastoma.